This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (26)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

H. E. HOBBS, F.R.C.S.; C. D. CALNAN, M.R.C.P.

AMA Arch Derm. 1959;80(5):557-563.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The use of quinacrine (Atabrine) for chronic discoid lupus erythematosus was discovered by Page ( 1951 ).¹ It had been used independently for the same purpose in Russia and some Eastern European countries since the publication of Prokoptchouk's work (1940).² Atabrine was soon found to be the most effective known treatment for discoid lupus erythematosus and a great deal safer than gold therapy. However, it has certain disadvantages in addition to the yellow staining of the skin, and other antimalarial drugs were assayed for their activity in controlling this condition. Chloroquine was shown to be equally effective (Goldman et al., 1953)³—in some cases more so—and had the additional merits of not staining the skin and of showing less tendency to produce troublesome drug rashes, such as the lichenoid dermatosis from quinacrine (mepacrine). Both drugs will cause gastrointestinal upset and a number of . . . [Full Text PDF of this Article]

Author Affiliations
London, England

Footnotes
Submitted for publication March 17, 1959. The Royal Free Hospital.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?